NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 18.104.22.168) - Tropomyosin receptor kinase C (TrkC) or NT-3 growth factor receptor is a protein encoded by the NTRK3 gene. It is involved in nervous system and probably heart development. Upon binding of its ligand neurotrophin-3, NTRK3 autophosphorylates and activates different signaling pathways, including the AKT and the MAPK pathways that control cell survival and differentiation.
Click here for sample report @ https://www.wiseguyreports.com/sample-request/2967008-nt-3-growth-factor-receptor-trkc-tyrosine-kinase-or-gp145
Top Companies mentioned
Daiichi Sankyo Co Ltd
Loxo Oncology Inc
NT 3 Growth Factor Receptor Industry Major Outlook
Pharmaceutical and Healthcare latest pipeline guide NT 3 Growth Factor Receptor - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for NT 3 Growth Factor Receptor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 22.214.171.124) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 2, 2 and 2 respectively..
NT 3 Growth Factor Receptor - Competitive Analysis
Key players are making innovative developments in NT 3 Growth Factor Receptor industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector
The report provides a snapshot of the global therapeutic landscape for NT 3 Growth Factor Receptor
The report reviews NT 3 Growth Factor Receptor targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
The report reviews key players involved in NT 3 Growth Factor Receptor targeted therapeutics and enlists all their major and minor projects.
The report assesses NT 3 Growth Factor Receptor targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type.
The report summarizes all the dormant and discontinued pipeline projects.
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2967008-nt-3-growth-factor-receptor-trkc-tyrosine-kinase-or-gp145
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
P: +44 208 133 9349
M: +1 646 845 9349